HSBC analyst Sidharth Sahoo has maintained a Hold rating on UnitedHealth Group while raising the stock's price target. The new target of $380 represents an increase from the previous $300, reflecting an updated valuation of the healthcare giant's prospects.

Rating and Target Details

The adjustment to the price target follows a review of UnitedHealth's market position. The following table summarizes the revised guidance provided by HSBC:

This revision signals the analyst's adjusted outlook on the company's future earnings and strategic direction within the healthcare sector.

UnitedHealth Group, Humana, and CVS Health have posted significant stock gains this year, outperforming popular technology names like Nvidia and Palantir. The rally represents a major reversal for these companies, which were previously among the top laggards on Wall Street. The primary driver for this recovery is the Donald Trump administration's increase in payments to insurers under Medicare Advantage plans.

The administration hiked payments by 2.48%, equivalent to $13 billion, significantly higher than the proposed 0.09%. This policy shift has enabled insurers to improve their financial forecasts. UnitedHealth Group raised its adjusted earnings per share outlook to $18.25 for the year, up from the previous estimate of $17.75. CVS Health, which operates the largest pharmacy chain and Aetna, increased its full-year profit guidance to a range of $7.30 to $7.50, compared to the earlier range of $7 to $7.20. Humana and Elevance Health also boosted their respective outlooks.

Wall Street analysts have responded to these developments by upgrading their price targets. Morgan Stanley increased its forecast for UnitedHealth Group stock from $453 to $468, while Bank of America and Leerink Partners set targets of $475 and $462, respectively. For CVS Health, Bank of America, Mizuho, and Morgan Stanley raised their outlooks to over $110, slightly above the current trading price of $104. Analysts at Bank of America, Evercore, and Mizuho also upgraded their forecasts for Humana.

The upgrades are supported by attractive valuations across the sector. Humana currently trades at a forward price-to-earnings ratio of 14, while CVS Health and UnitedHealth Group have ratios of 14.10 and 22, respectively. Investors are now looking toward upcoming earnings reports for further performance insights. UnitedHealth is scheduled to publish its results on July 16, while CVS and Humana will release their numbers on August 5 and July 29, respectively.

Stock Performance and Analyst Targets